
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is a clinical-stage biopharmaceutical company developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company's lead candidate, vidofludimus calcium, has a novel dual-mechanism with both neuroprotective and anti-inflammatory effects, making it a promising treatment for relapsing multiple sclerosis (RMS) patients. With the Phase 3 clinical trial expected to report topline data by the end of 2026 and plans for a confirmatory Phase 3 program for primary progressive MS, Immunic has strong potential for future growth. However, the recent reverse stock split and dilution risks may outweigh the near-term clinical upside. Investors should also consider potential risks such as clinical/regulatory, financial, and market share risks before investing in this company.
Bears say
Immunic is facing multiple challenges in the near term, including potential technical pressure surrounding reverse split, follow-on financing activity, and changes in shareholder base that may impede its progress. Additionally, the company's late-stage program and capital-intensive nature may lead to a sub-optimal financial situation, despite its recent financing efforts. Finally, Immunic must prove the effectiveness and commercial viability of its lead asset in a competitive market, which may be hindered by its limited cash reserves and shareholder overhang.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares